Search research articles
Contact Us
Filters
Showing results (531-540 of 703) with videos related to
Page
of 71
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 3, 2020
Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma
M T Tetzlaff, C Adhikari, S Lo, et al.
Human Molecular Genetics
|
July 28, 2020
Multiplex melanoma families are enriched for polygenic risk
Matthew H Law, Lauren G Aoude, David L Duffy, et al.
Nature Medicine
|
September 24, 2025
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial
Georgina V Long, Nitya Nair, Daniel Marbach, et al.
Cancer Research Communications
|
February 3, 2025
Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma
Eva Munoz-Couselo, Ainara Soria Rivas, Shahneen Sandhu, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 8, 2024
Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors
Florentia Dimitriou, Marlana M Orloff, Erica C Koch Hein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 31, 2023
Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results
Adi Diab, Helen Gogas, Shahneen Sandhu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 6, 2024
Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma
Georgina V Long, James Larkin, Dirk Schadendorf, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 27, 2017
Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials
Dirk Schadendorf, Georgina V Long, Daniil Stroiakovski, et al.
Journal of Translational Medicine
|
September 7, 2020
Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy)
Paolo A Ascierto, Igor Puzanov, Sanjiv S Agarwala, et al.
The Lancet. Oncology
|
July 22, 2017
Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial
Georgina V Long, Victoria Atkinson, Jonathan S Cebon, et al.
Page
of 71
Search research articles
Search
Showing results (531-540 of 703) with videos related to
Sort By:
Page
of 71
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 3, 2020
Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma
M T Tetzlaff, C Adhikari, S Lo, et al.
Human Molecular Genetics
|
July 28, 2020
Multiplex melanoma families are enriched for polygenic risk
Matthew H Law, Lauren G Aoude, David L Duffy, et al.
Nature Medicine
|
September 24, 2025
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial
Georgina V Long, Nitya Nair, Daniel Marbach, et al.
Cancer Research Communications
|
February 3, 2025
Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma
Eva Munoz-Couselo, Ainara Soria Rivas, Shahneen Sandhu, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 8, 2024
Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors
Florentia Dimitriou, Marlana M Orloff, Erica C Koch Hein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 31, 2023
Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results
Adi Diab, Helen Gogas, Shahneen Sandhu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 6, 2024
Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma
Georgina V Long, James Larkin, Dirk Schadendorf, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 27, 2017
Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials
Dirk Schadendorf, Georgina V Long, Daniil Stroiakovski, et al.
Journal of Translational Medicine
|
September 7, 2020
Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy)
Paolo A Ascierto, Igor Puzanov, Sanjiv S Agarwala, et al.
The Lancet. Oncology
|
July 22, 2017
Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial
Georgina V Long, Victoria Atkinson, Jonathan S Cebon, et al.
Page
of 71